歌禮制藥-B(01672.HK):啟動ASC40(地尼法司他)治療痤瘡III期臨牀試驗
格隆匯12月5日丨歌禮制藥-B(01672.HK)發佈公吿,啟動脂肪酸合成酶(FASN)抑制劑ASC40(地尼法司他)治療中、重度尋常性痤瘡的III期臨牀試驗。
這項III期臨牀試驗是一項在中國開展的隨機、雙盲、安慰劑對照、多中心的臨牀試驗,旨在評估ASC40治療中、重度尋常性痤瘡的安全性和療效。480例中、重度尋常性痤瘡受試者將被按照1:1的比例隨機分至一個活性藥物組和一個安慰劑對照組,接受每日一次口服50毫克ASC40或匹配的安慰劑治療,為期12周。復旦大學附屬華山醫院項蕾紅教授擔任這項III期臨牀試驗的主要研究者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.